Research highlight examines age-specific targets for anti-tumor T cell function
Published in Biology, Drugs development & discovery, Immunology, Journals.
Published October 31, 2026.
An October 29 research highlight in Cell Research examines why age may matter when selecting targets to improve anti-tumor T cell function. It discusses an earlier Cell study of Dusp5 and Zfp219, rather than reporting a new clinical trial.
In the original experiments, single-cell CRISPR screens identified two different routes to stronger CD8 T cell responses. Dusp5 deletion increased ERK signaling and proliferation. Zfp219 deletion altered accessibility of cytotoxic gene programs and improved anti-tumor responses specifically in aged mouse hosts.
The mouse findings included enhanced activity alongside immune checkpoint inhibition. Human tumor samples showed an association between higher expression of the corresponding gene, ZNF219, and poorer survival after immunotherapy.
That association does not show that inhibiting ZNF219 will benefit patients. The work remains a target-discovery finding requiring further validation, including human loss-of-function studies. It does not establish a general rejuvenation treatment.
Sources: Frangieh, C.J. and Izar, B., Cell Research, October 29, 2026; original Cell study, first published online July 29, 2026 (October 15 issue).